Clinical Trials Browser

Phase 2/3 × Recurrence × Lymphoid × Clear all

Cytokine Release Syndrome, Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07366801 2026-01-26

Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies

Phase 2/3 Recruiting

64 enrolled

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04442022 2025-10-03

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2/3 Recruiting

501 enrolled

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05595447 2025-03-12

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Phase 2/3 Recruiting

20 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT01518517 2022-02-02

GRASPIVOTALL

Phase 2/3 Completed

85 enrolled 13 charts

LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02910063 2021-01-13

Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL

Phase 2/3 Completed

41 enrolled 18 charts

LymphoidOther hematologic neoplasm

Leukemia, Neoplasms, Recurrence, Lymphoma, B-Cell

NCT01197560 2019-11-25

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2/3 Completed

111 enrolled 20 charts

Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03391726 2018-01-05

CCFRRBL

Phase 2/3 Unknown

20 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell

NCT00070187 2013-10-17

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Phase 2/3 Completed

24 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, Recurrence

NCT01423032 2011-08-25

Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)

Phase 2/3 Completed

96 enrolled

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trials

NexCAR19

Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

GRASPIVOTALL

Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

CCFRRBL

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)